Abstract Friedreich's ataxia is a multisystem disorder of mitochondrial function affecting primarily the heart and brain. Patients experience a severe cardiomyopathy that can progress to heart failure and death. Although the gene defect is known, the precise function of the deficient mitochondrial protein, frataxin, is not known and limits therapeutic development. Animal models have been valuable for understanding the basic events of this disease. A significant need exists to focus greater attention on the heart disease in Friedreich's ataxia, to understand its longterm outcome, and to develop new therapeutic strategies using existing medications and approaches. This review discusses some key features of the cardiomyopathy in Friedreich's ataxia and potential therapeutic developments.
Introduction
Friedreich's ataxia (FA) is the most common inherited ataxia in man. It is a relentlessly progressive cardio-and neurodegenerative disease typically beginning in early to mid childhood that within 10-15 years of onset leads to loss of motor skills and, ultimately, inability to stand or walk [31] . Patients experience a primary neurodegeneration of the dorsal root ganglia leading to the hallmark clinical findings of progressive ataxia [14, 69] , debilitating scoliosis, and severe cardiomyopathy that causes death in the third to fifth decade of life [58] . Significant other problems include diabetes in 10% of patients and severe scoliosis requiring surgical correction. No cure exists.
Genetics of FA
The incidence of FA is approximately 1 in 30,000 people (prevalence of 1:50,000). It occurs with equal frequency in males and females [78] and has a carrier frequency of 1:60-1:120 [20, 21, 72, 84] . Genetically, FA is passed on as an autosomal recessive trait caused predominantly by a GAA triplet expansion in the first intron of the human frataxin gene (FRDA) on chromosome 9q21.11 (reviewed in [57, 58] ). Patients frequently have 600-1,200 repeats of this GAA triplet, predicted functionally to ''silence'' the human FRDA gene through the formation of triple-stranded DNA [76] as a result of the GAA repeats forming nonWatson-Crick pairings with the bases of the DNA double helix [23] . The result is transcriptional inhibition and partial silencing of the FRDA locus, with severely reduced expression of the protein, frataxin. Thus, patients with FA have levels of frataxin ranging from 5% to approximately 25% of normal. The heterozygous parents are not affected. A correlation exists between the GAA repeat number and the onset and severity of clinical symptoms, with higher repeat numbers related to more severe disease and cardiomyopathy [22, 55, 64] .
Clinical Cardiac Findings in FA
The cardiomyopathy in FA is a significant problem, affecting virtually all hearts to a variable degree [31, 35, 50] .
The heart becomes hypertrophic, typically maintaining adequate systolic function [41] until shortly before death [64] . Arrhythmias are common and frequently intractable. Cardiac magnetic resonance imaging (MRI) demonstrates the severe hypertrophy very well, as shown in Fig. 1 , but echocardiography also is excellent for long-term evaluation of left ventricular wall thickness and function (Fig. 2) . Both ventricles are affected, and arrhythmias are common, especially those of atrial origin. Although the primary cause of death in FA is heart failure [30] , surprisingly little has been written about the natural history and pathology of the FA heart, with most publications focusing instead on the dramatic neuropathology. Since 1966, fewer than 200 publications have been written on the heart in FA, compared with more than 2,500 publications reporting on the neurologic findings of this disease.
The cardiomyopathy of FA most often presents symptoms in the second to third decade of life, although a significant range exists. For example, a hypertrophic heart can be the initial finding, resulting even in transplantation before the diagnosis of FA [43] , whereas other patients may not manifest cardiac symptoms. Findings have shown significantly less myocardial energy generation in FA patients than in control subjects. The degree of reduction correlates with the degree of hypertrophy [6] and may even precede its development [48] . Use of the antioxidant and coenzyme Q mimetic, idebenone, may help to improve myocardial energy deficiency and decrease hypertrophy both by acting as an antioxidant and by enhancing electron transport within mitochondria [51, 74] . This has been the case in short-term (1 year) studies. However, longer-term studies using idebenone have shown a reduction in cardiac mass but not a decrease in arrhythmias or progression of heart failure [59, 87] , and there is no research on the clinical relevance of these changes. Antioxidant therapies have not shown any benefit or improvement in terms of neurologic or cardiac symptoms [40, 49] . However, a key limitation of antioxidant therapies is that they frequently have a very short half-life and thus are not at therapeutic levels. Therefore, measures to extend the half-life of these agents may improve their efficacy.
Multiple authors have noted that the cardiac phenotype is quite variable [33, 41] and that cardiac MRI of left ventricle (LV) mass correlates with the GAA repeat number and longer duration of disease [64] . Hypertrophy may progress to dilation in time, giving the appearance by echocardiography that ventricular hypertrophy has improved [33] . Earlier echocardiography and radionuclide studies demonstrated good systolic function of both ventricles but impaired diastolic filling [19, 56] . These findings are consistent with the histologic appearance of fibrosis in the LV wall and suggest that there may be diastolic dysfunction in the FA heart. Virtually all hearts are affected in FA, and subtle electrocardiographic (ECG) findings are frequently among the earliest findings of cardiomyopathy. In Fig. 3a and b, ECGs from two patients demonstrate the nonspecific T-wave changes often seen in the lateral chest leads. However, ECG is not diagnostic of FA and has not shown utility for prognosis in this disease.
At the microscopic level, changes in the LV include cardiomyocyte hypertrophy, focal necrosis, and diffuse fibrosis [35] . Electron microscopy shows mitochondrial proliferation, loss of contractile sarcomeres, and electron dense particles within mitochondria that may represent iron deposition [52] . This is strikingly similar to what is found in the mouse heart with frataxin (FXN) deficiency (Fig. 9) . Recent studies of patients with FA using cardiac MRI and adenosine have shown that the heart has a significantly decreased myocardial perfusion reserve index, which parallels the onset of metabolic syndrome [65] . Furthermore, the impaired perfusion reserve does not correlate with degree of hypertrophy or fibrosis, suggesting that this may be an important tool for identifying potential therapeutic targets to prevent the development or progression of heart failure.
Basic Findings and Mouse Models
The frataxin protein is an essential and highly conserved protein expressed in most eukaryotic organisms (reviewed by Puccio and Koenig [61] ). For example, more than 90% homology exists between the mature frataxin proteins of man and mouse (Fig. 4) . The FXN protein is targeted to mitochondria and appears to function in mitochondrial iron homeostasis [36] , notably in the de novo biosynthesis of iron-sulfur cluster proteins [83, 85, 92] and probably heme [71, 91] . The 210 amino acid precursor FXN protein (23.1 kDa) contains a mitochondrial targeting sequence at the amino terminus that is processed in two steps by the mitochondrial matrix processing peptidase as it is imported into the matrix [9] , yielding a 130 amino acid, 14.2-kDa protein [12, 77] . In its absence, free iron accumulates in mitochondria, with loss of activity of Fe-S-containing proteins [45, 73] as well as energy production [47, 48] . From a therapeutic standpoint, this is important: if the cell ever encounters frataxin protein or mRNA, it is handled appropriately [60] . Currently, treatment options logically include antioxidants and iron chelation [38, 70] . Although early clinical trials have shown mild biochemical improvement [32] , they have not been clinically effective. It also is probable that significant and permanent damage has already occurred by the time the diagnosis of FA is made, and recent studies have supported earlier intervention [4] . Animal models mimicking FA have been invaluable both for the study of the basic biology and for the clinical implications of this disease. Although highly useful, each of these models also has significant limitations. Two basic strategies have been used to recapitulate this disease in the mouse. The first strategy accomplishes a conditional ablation of the mouse FRDA gene by the Puccio lab, in which exon 4 of the FRDA gene is deleted using Cremediated excision in a tissue-specific fashion [62] . This causes complete absence of the FXN protein only in the target tissues. This is necessary because complete ablation of the FRDA gene in the mouse is embryonically lethal, demonstrating the importance of early frataxin expression [13] . However, when the FRDA gene is ablated in heart and brain or in heart alone (skeletal muscle expression also is ablated but has no phenotype), then significant phenotypes are generated that recapitulate many features of FA. For example, mice in which the FRDA gene is ablated in brain (neural tissues) and heart demonstrate a severe neurologic phenotype, cardiomyopathy (dilated), and a very short life span [62] , with less than 20% surviving beyond 30 days of life. These mice grow poorly (Fig. 5a , b) compared with their heterozygous littermates, demonstrating ataxia and loss of proprioception in behavioral studies such as the rotarod. As with FA in the human heart, clear evidence points to iron deposition in the mouse hearts, as shown by Perls' stain ( Fig. 6a, b) , and to severe fibrosis (Fig. 6c, d ). Analysis of hearts from the FRDA KO animals shows that they have statistically higher apoptosis counts than agematched wild-type controls, indicating ongoing cardiomyocyte loss (Fig. 7a-c) . In contrast, mice in which the FRDA gene is ablated only in sarcomeric tissues (heart and skeletal muscle) predictably do not have ataxia but experience a cardiac phenotype of hypertrophic cardiomyopathy very reminiscent of the human heart disease [90] . Thus, this strategy mimics the phenotype of the human disease well but not the correct genotype. The mice also are lacking any FXN protein in the affected tissues (''knocked out''), whereas humans have residual low-level expression of FXN protein and thus a more variable presentation. These mice are especially useful for studying the histology of FA and for developing protein or enzyme replacement therapies such as with cell-penetrant peptide fusion proteins [68] (e.g., transactivator of transcription (TAT)-frataxin). The cardiac pathology for these conditional knockout mice frequently is very similar to that for the hearts of patients with FA. In addition to iron deposition in the myocardium mentioned earlier, they also show a cardiomyopathy on echocardiography with evidence of diastolic dysfunction. For example, Fig. 8 shows the echocardiograms of a normal littermate mouse (Fig. 8a, b) and a conditional FRDA knockout mouse (Fig. 8c, d) M-mode of the normal mouse (Fig. 8a) shows good LV function and a normal mitral inflow pattern based on the E-A waveform. In panel Fig. 8c , the M-mode demonstrates a dilated, poorly contractive LV with a slower heart rate and reversal of the E-A waveforms (Fig. 8d) . Examination of the cardiomyocyte ultrastructure in these mice by electron microscopy is particularly informative. The normal mouse heart shown in Fig. 9a demonstrates normally shaped mitochondria tightly packed between rows of sarcomeres. The alignment of the sarcomeres is highly regular and robust. In contrast, Fig. 9b demonstrates the severe disorganization of the cardiomyocyte from an FRDA conditional knockout mouse heart. In this case, very few sarcomeres remain, and mitochondria have proliferated extensively. There is little evidence of the tight relationship between energy-generating mitochondria and the site of ATP utilization (sarcomere) seen in the normal mouse cardiomyocyte. This parallels exactly what is found in the human heart [52] and has strong clinical implications for patients with FA. Ultimately, LV contractile function decreases due to loss of contractile proteins and disruption of the normal mitochondria-to-sarcomere relationship.
In the second strategy, mice have been generated that have a ''knock-in'' of the pathologic human FRDA gene with GAA repeats into the mouse by both the Pook lab [2] and the Pandolfo lab [53] . In these models, the native mouse FRDA genes have been ablated (KO), leaving expression of frataxin dependent only on the human FRDA gene, which also contains the triplet expansion region. The phenotype is less severe in these animals, but the genotype more accurately mimics the human disease. These animals have been especially useful for studying therapeutic approaches that increase transcription of the FRDA gene containing the triplet expansion, such as histone deacetylase (HDAC) inhibitors [63] . Fig. 8 Echocardiography of the FRDA knockout mouse (FRDA KO) heart and wild-type control heart. Littermate mice were 28 days of age and underwent echocardiography using a VisualSonics highfrequency ultrasound machine using 1-2% isofluorane inhaled anesthetic. a, b M-mode ultrasound of wild-type mouse in short axis demonstrating vigorous contraction and high heart rate (407 bpm). Fig. 9 Electron microscopy of the FRDA knockout mouse (FRDA KO) heart and wild-type control heart. Littermate mice were 28 days of age at the time of the study. a Wild-type mouse showing normal mitochondria (''m'') in rows between abundant, well-ordered sarcomeres (''s''). b Conditional FRDA KO mouse with ablation of the FRDA locus in the heart and brain (NSE-Cre promoter). Note extreme proliferation of enlarged mitochondria in b. There is a severe loss of sarcomeres (''s''). Bar = 1,000 nm in both a and b
Therapy for Mitochondrial Disorders
Repair of mitochondrial disorders such as FA is necessarily more complex than replacement of a cytosolic gene product and must consider not only the need to target and cross multiple membranes in mitochondria but also the fact that many enzymes in mitochondria are hydrophobic and not readily soluble. Additionally, many of the mitochondrial gene defects cause severe neurologic symptoms as the primary or most prominent phenotype, and drug delivery across the blood-brain barrier is notoriously difficult [3] . As a result, therapies for mitochondrial defects, such as with coenzyme Q for OXPHOS diseases, currently focus primarily on using small molecules to enhance flux through the electron transport chain [29] or on altering the precursor pool of substrate to avoid the defective metabolic pathway such as changing dietary intake of fatty acids to avoid medium chain lipids in medium-chain acyl-dehydrogenase deficiency [25] . To date, success with gene therapy has been very limited [46] , and enzyme replacement therapy (ERT) for mitochondrial defects in the intact animal has had no success, much less correction of a defect across the blood-brain barrier.
Background on ERT
Currently, ERT, or protein replacement therapy, is a wellestablished therapy for human diseases. The most common example is insulin injections for the treatment of diabetes. Other examples would be Pompe's disease [10] with recombinant human acid a-glucosidase and Gaucher disease with imiglucerase [26] . Multiple pharmaceutical houses, such as Genzyme, Shire, BioMarin, and Eli Lilly, produce proteins from bacterial or human cell lines for ERT. Surprisingly, ERT for mitochondrial disorders has not had significant success, most likely due to the dual difficulty of achieving cell penetration by a recombinant protein and import of the protein into the mitochondrial matrix. Thus, no cures currently exist for mitochondrial disorders, with most therapies providing ''work-around'' solutions to the metabolic defect. The combination of ERT with the power of cell-penetrating peptides such as TAT to deliver a therapeutic protein to mitochondria is a logical and exciting possibility for addressing mitochondrial disorders [66] .
Background on Cell-Penetrant Peptides
The cell-penetrant peptide, TAT, is a protein transduction domain that has been used to transduce multiple cargos such as proteins into cells and tissues of animals and cells in culture. As a short cationic peptide derived from the larger TAT protein of HIV, TAT has cell-penetrant properties [17, 28, 79] . Cell-penetrant peptides typically are small cationic peptides that can transport a cargo of molecules such as proteins, peptides, or oligonucleotides into cells that otherwise cannot absorb large molecular weight compounds. Various transduction peptides such as polyarginine, synB5, antennapedia, herpes simplex virus type 1 protein, and many others have been used to transport complex proteins into cells and have shown promise as therapeutic strategies for several disease conditions [18, 54, 75, 86] . Delivery of a cargo by a cell-penetrant peptide has been accomplished for multiple organelles such as mitochondria (Fig. 10 ) [17] , lysosomes [93] , and the nucleus [39] , which are capable of delivering a cargo across the placenta [16] . Finally, TAT has already been used to replace missing cytosolic enzymes such as purine nucleoside phosphorylase [86] in animal models of disease and in a cell culture mitochondrial model of human disease (i.e., lipoamide dehydrogenase deficiency) [67] . Additionally, it is not necessary to restore all the missing protein to restore adequate amounts of enzymatic activity in mitochondria [88] . This would be key for the human disease, in which patients have reduced expression of the frataxin protein compared with some of the current animal models in which the gene product has been ablated [62, 90] . Thus, cellpenetrant peptides offer an exciting potential to deliver Heart Brain TAT-mMDH-eGFPm Control Fig. 10 Transduction of a TAT-fusion protein into tissues. A TATmMDH-eGFP protein was expressed and purified from bacterial culture, then injected into a wild-type mouse intraperitoneally. The mouse was killed 24 h later, and heart and brain were imaged using confocal microscopy. In both the heart and brain, a strong green fluorescent signal is present indicating the presence of eGFP in tissues. The control tissues were taken from a noninjected mouse and show minimal autofluorescence protein replacement for many inherited and acquired cardiac diseases [88] . This is important because delivery of drugs and therapeutic compounds is primarily limited by their ability to penetrate the cell membrane. The bioavailability of compounds targeted to intracellular sites also depends on the conflicting requirements of their being sufficiently polar for administration and distribution yet nonpolar enough to diffuse through the nonpolar lipid bilayer of the cell [3] . In addition, the molecular weight of most drugs that can easily traverse the lipid membrane is approximately 500 Da [44] . Thus, most successful compounds have narrow physical characteristics. Many promising drugs fail because they fall outside this range, and efforts to make them available may be toxic. In addition to this, many sites of action for presumed therapeutic compounds, such as enzymes or regulatory proteins, require processing and targeting of the compound once inside the cell. This step alone represents a significant hurdle to the development of many strategies for repairing defects within a cell. Already, TAT has been used to replace missing cytosolic enzymes such as purine nucleoside phosphorylase in animal models of disease [86] . Thus, cell-penetrant peptides offer an exciting potential to overcome many of these problems for ERT.
We [16, 17] and other investigators [67] have shown that TAT can transduce the mitochondrial membranes to deliver a cargo. Figure 11 demonstrates the hypothesis and evidence of a cell-penetrant peptide, TAT, attached via a mitochondrial targeting signal from mitochondrial malate dehydrogenase (mMDH) to enhanced green fluorescent protein (eGFP). This protein is able to move across the cell membrane and localize in the mitochondrial matrix independently of the mitochondrial import apparatus where it is processed appropriately. The mechanism whereby this occurs is not well understood but appears to involve sodium channels in the mitochondrial membranes [68] . This is in contrast to the more complex multistep import of the natively expressed and imported mitochondrial protein shown in Fig. 12 . In this case, the nuclear encoded protein is first translated in the cytosol, recognized by the mitochondrial receptor, imported via the ATP requiring import apparatus, and processed and folded in the matrix. Irrespective of the mechanism whereby a replacement protein reaches mitochondria, there are three key points regarding ERT for mitochondrial defects:
1. The native mitochondrial targeting sequence may be necessary for maximal restoration of enzymatic function. Rapoport et al. [66, 67] showed that it was necessary to have the lipoamide dehydrogenase (LAD) mitochondrial targeting sequence for maximal restoration of LAD activity in patients with the mitochondrial disorder: LAD using TAT-LAD [5] . Deleting the mitochondrial targeting sequence (TAT-D-LAD) restored a significantly lesser amount of LAD activity within mitochondria. This is a subtle but important point to consider: TAT can move both ways across a membrane and thus pull the therapeutic cargo out of mitochondria. By including the mitochondrial targeting sequence, the matrix-processing peptidases recognize the sequence and clip it. The cargo is left in the matrix, whereas the TAT peptide can transduce out of the mitochondrion (Fig. 11a) . Repeated dosing should therefore result in accumulating amounts of cargo in mitochondria over time. Fig. 11 A TAT-fusion protein transduction into mitochondria. a The positively charged peptide of TAT interacts with negative charges of the cell membrane (not shown) and the mitochondrial phospholipid membrane to initiate transduction of the TAT-mMDH-eGFP fusion protein across both mitochondrial membranes. Inside the matrix, the mitochondrial-processing peptidase (MPP) clips the mMDH sequence, leaving the GFP cargo trapped in the matrix while the TAT-mMDH peptide diffuses out. The transduction into mitochondria is independent of membrane potential and ATP status, and is not receptor mediated. The asterisk indicates the contact site. b Fulllength TAT-mMDH-eGFP (cartoon A) was incubated with isolated mitochondrial matrix proteins and separated by 12% SDS-PAGE followed by blotting to membrane and probing for GFP by Western blotting using anti-GFP antibody (Promega). Cartoons A, B, and C show the progressive predicted sizes after digestion with the contents of the mitochondria and are present on the Western blot at the predicted sizes Pediatr Cardiol (2011) 32:366-378 373 2. To restore activity of the native complex, TAT is capable of transducing single components of very large enzyme complexes. Proteins are normally imported into mitochondria in denatured form [24] , and mitochondria are thus well equipped to refold proteins into an active configuration for incorporation with larger enzyme complexes. Because cell-penetrant peptides depend on the fusion protein being sufficiently denatured to make the penetrant peptide available for initiation of transduction, protein transduction technology is perfectly suited for ERT in mitochondria. 3. It is not necessary to restore all the missing protein to restore adequate amounts of enzymatic activity in mitochondria. Small amounts of normal protein may be adequate to repair the defect. This concept also is important for organs into which it is typically difficult to deliver drugs, such as the brain or placenta. Findings have shown that TAT crosses the blood-brain barrier and placenta quite well [7, 16, 79] . This opens the possibility of initiating ERT for mitochondrial defects before birth or for neurologic disorders that manifest well after birth.
Treatment Considerations
The cardiac output of affected patients experiencing FA often may reflect the characteristics of a restrictive cardiomyopathy with a greater dependence on heart rate to maintain adequate output. If this is the case, there will predictably be an increase in LV filling pressures, with resultant atrial arrhythmias commonly seen in advanced FA. Use of afterload-reducing agents, such as losartan or angiotensinconverting enzyme (ACE) inhibitors, may be beneficial in long-term treatment of this heart disease. It also may decrease the physiologic incentive for cardiac hypertrophy and energy utilization by ventricular cardiomyocytes. In contrast, those agents that slow heart rate and decrease oxygen utilization, such as carvedilol or other b-adrenergic blocking agents, may not be well tolerated. For example, if diastolic filling is impaired due to a restrictive characteristic of this cardiomyopathy, then slowing of the heart rate would predictably decrease cardiac output. The literature is mixed with regard to the use of b-adrenergic blocking in cardiomyopathies of childhood. Isolated reports describe the use of high-dose b-adrenergic blocking agents in FA as either beneficial or of little value [40, 42] . For example, carvedilol is beneficial in adult-onset ischemic cardiomyopathy but has little effect on cardiomyopathies of childhood, in which the etiology of the heart failure is much different and variable [82] . Currently, our treatment options are very limited and logically include antioxidants, such as idebenone, and iron chelation, such as with deferiprone [38, 70] . In addition, management of heart failure symptoms often requires conventional therapies with afterload reduction, salt restriction, and diuresis. Although early clinical trials have shown modest biochemical improvement [32] , these therapies have not resulted in substantial sustained clinical improvement because they are designed to control downstream events resulting from the loss of FXN, and the cellular damage is progressive. It also is probable that significant and permanent damage has already occurred by the time the diagnosis of FA is made, making these therapeutic approaches less effective. Recent studies have supported earlier intervention. For example, according to the findings of Boddaert et al. [4] , iron chelation with a membrane-permeant chelator that shuttles iron to transferrin reduced the brain iron load and had the greatest effect in the youngest patients. If confirmed, this is a strong argument to begin therapy for FA as early as possible and supports the drive toward newborn screening for FA (see commentary by Isaya [37] ). Expansion of newborn screening to include diseases such as FA has been advocated in a recent publication describing recommendations for uniform newborn screening [89] . Work is underway at Mayo Clinic to develop a protein-based assay to screen newborns for FA (supported by the Friedreich's Ataxia Research Alliance). However, despite concerted clinical efforts with antioxidant and iron chelation strategies, no therapy has been substantially effective for this disease.
Transplantation also has been offered as a therapy for the severe heart failure found in FA, but it is not commonly performed. Approximately five transplantation cases have been reported in the literature, with the first dating to 2001 [43] . As reported, all the patients did well with their transplant. Several showed significant improvement in their motor skills and strength, suggesting that part of the symptoms of neuromuscular disease may have resulted from severe congestive heart failure (CHF) instead [80] . Although FA typically is considered a hypertrophic heart disease, several of the patients exhibited dilated cardiomyopathy with severe CHF (New York Heart Association class 3 or worse) at the time of transplantation. This also has been described by earlier authors [1, 11] and may represent a terminal stage of the cardiomyopathy [8, 33] . Interestingly, progression of neuromuscular findings, such as ataxia, was arrested for prolonged periods for several of these patients after transplantation [43, 80] . No significant deleterious effects of immunosuppression have been noted beyond prednisone-induced diabetes [80] . Key considerations for transplantation in FA include the life span of the patient, which typically will exceed the life of the transplant [81] , and the degree of associated comorbidities in FA, such as severe scoliosis causing respiratory compromise. Other centers have since followed suit and currently offer transplantation for select patients with FA as well as other neuromuscular disorders.
Summary
Friedreich's ataxia is a prime example of the multisystem effects that mitochondrial diseases can present with in clinical medicine. Thus, cardiomyopathy may be a presenting finding (murmur at examination), with the diagnosis of ataxia following some years later. More commonly, ataxia is the finding at presentation. Treatment of FA is confounded by the elusive function of the frataxin protein and the need to deliver a therapy into mitochondria. It also is hindered by the lack of clinical understanding of the heart disease in FA. Particularly lacking are long-term studies. New discovery certainly is rapidly advancing our understanding of the basic biology of FA, and the lessons learned have great potential for application to other mitochondrial diseases. Thus, a great need exists to understand the natural history and outcome of the heart disease in FA. But given the relatively small amount of literature on the heart in FA compared with that for the neurologic and histologic phenotype, greater emphasis on clinical studies and trials examining this mitochondrial cardiomyopathy are urgently needed to advance the development of therapies.
Multiple lines of investigation being aggressively pursued to develop innovative strategies likely will have application to other mitochondrial disorders as well. Two strategies worthy of note directly attack the problem in FA. The goal of the first strategy is to improve the expression of the frataxin protein by increasing ability of the DNA transcription machinery to read through the diseased FRDA gene. Work on this strategy has been conducted by Joel Gottesfeld, who reported earlier that histone deacetylase (HDAC) inhibitors would increase the frataxin mRNA transcript and could increase FXN protein levels of cells in culture [34] . When HDAC inhibitors were applied to the FA mice with expression of the diseased human FRDA gene (the ''knock-in'' mouse described earlier), an increase in FXN protein occurred [63] . This strategy also has significant potential for application to other triplet expansion diseases.
Applying the second strategy, our laboratory has pursued an enzyme-replacement approach, which genetically fuses the missing protein, FXN, to a cell-penetrant peptide, TAT, to deliver the protein into the cell and mitochondria. We reported earlier that TAT was capable of pulling exogenous proteins across cell and mitochondrial membranes to deliver a cargo to the matrix of mitochondria in both isolated cells and tissues of the intact mouse [15, 17, 68] . In fact, TAT even crosses the placenta to deliver proteins to mitochondria of the fetus [16] , thus offering the potential for initiating therapies for mitochondrial defects before birth. Studies underway use the conditional ablation knockout mice from the Puccio lab to explore this approach. Early results are highly promising (data in preparation), and other investigators also have recently reported that TAT can deliver therapeutic proteins in mouse or human models of disease [27, 67, 86] .
